Resources from the same session
LBA41 - LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
Presenter: Zarnie Lwin
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1019O - Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Nehal Lakhani
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1020O - A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
Presenter: Manish Sharma
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1021O - Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies
Presenter: Michael Millward
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA41 and 1019O
Presenter: Ignacio Melero
Session: Proffered Paper - Investigational immunotherapy
Resources:
Webcast
Invited Discussant 1020O and 1021O
Presenter: Maria Rescigno
Session: Proffered Paper - Investigational immunotherapy
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Silvia Formenti
Session: Proffered Paper - Investigational immunotherapy
Resources:
Webcast